Princeton, NJ, 2022年5月17日. Certara, Inc., a global leader in biosimulation, today announced that the Company was Certified™ by Great Place to Work® in its first year of participation. The prestigious award is based entirely on what current employees say about their experience working at Certara. This year, 88% of employees said it’s a … Continued
ニュージャージー州プリンストン、2022年5月3日2022 ― バイオシミュレーションのグローバルリーダーであるCertara, Inc.は、本日、当社のSimcyp COVID-19ワクチンモデルが、Therapeutic Impact部門で2022年エジソン賞（ブロンズ）を受賞したことを発表しました。The Simcyp COVID-19 Vaccine Model, which is incorporated in Certara’s Vaccine Simulator, uses biosimulation and computer-generated, virtual populations to facilitate … Continued
PRINCETON, N.J., 2022年4月26日 — Certara, Inc., a global leader in biosimulation, and Chemaxon, a leading chemical and biological software development company, today announced a strategic partnership to accelerate drug discovery research through integrated scientific informatic workflows to modernize pharmaceutical research. This partnership provides interconnectivity between Certara’s D360 Scientific Informatics software and Chemaxon’s Design … Continued
PRINCETON, N.J.— 2022年4月12日 – Certara, Inc., a global leader in biosimulation, today announced that it has issued its inaugural environmental, social and governance (ESG) report. The report “Innovating to Improve Patient Lives” outlines Certara’s approach to a responsible ESG framework across four pillars: 1) health and social impact of our software and services, … Continued
Delivers advanced analysis to support scientific findings for regulatory submissions PRINCETON, N.J.— 2022年3月30日 – Certara, Inc., a global leader in biosimulation, today announced the release of the SEND Explorer® Product Family version 10.0. SEND Explorer allows scientists to interactively investigate study data, to efficiently identify dose-response relationships and to effectively communicate data trends … Continued
PRINCETON, N.J.— 2022年3月29日 — Certara, Inc, a global leader in biosimulation, and Pharmacometrics Africa NPC, today announced a partnership with the University of Cape Town (UCT) to support its fellowship program for doctoral-level scientists from Africa. The Fellowship program builds scientific and leadership capability in the region by enhancing the skills of scientists and … Continued
プリンストン、ニュージャージー：2021年3月29日 バイオシミュレーションのグローバルリーダーであるサターラ（Nasdaq：CERT) はCERT), a global leader in biosimulation, today announced the appointments of Stephen Duffull, Ph.D., as a Senior Scientific Advisor and Mark Sale, M.D., as Vice President in the Integrated Drug Development (IDD) team. “We are pleased to welcome Steve and Mark to Certara as we continue … Continued
Princeton, N.J., 2022年3月17日 — Certara, Inc. today announced a four-year, framework service contract with the European Medicines Agency (EMA) to advance regulatory decision-making in the human medicines domain with advanced statistical and pharmacoepidemiological research. The Company will develop innovative study designs and conduct pre- and post-authorisation real-world, risk-benefit studies. “On their own, trial … Continued
Enhances and speeds up small molecule and biologics discovery research PRINCETON, N.J.— 2022年3月8日 – Certara, Inc., a global leader in biosimulation, today announced the release of D360 Scientific Informatics software version 22.0. This new release of D360 software delivers new capabilities to better understand sequence-activity relationships (SeqAR) and guide molecular design. D360 software … Continued
Join us at MassBio’s Rare Disease Day on February 28 to hear from one of our rare disease development experts. PRINCETON, NJ– Today, Certara®, the global leader in biosimulation, launches a new practice area dedicated to advancing rare disease drug development. More than 7,000 rare diseases impact millions of people worldwide many of which have … Continued
